Oprah and Michael Pollan on Psychedelics and Mental Health

In this Oprah podcast interview, journalist Michael Pollan, who also holds a professorship at Harvard and wrote the 2018 book "How to Change Your Mind," discusses renewed scientific interest in psychedelics such as psilocybin, LSD, ayahuasca, and MDMA. Four guests, including GoDaddy founder and Vietnam veteran Bob Parsons, describe guided psychedelic experiences with PTSD, OCD, anxiety, and grief. Oprah notes upfront the conversation is not medical advice, and Pollan is careful to separate personal accounts from early, still-developing trial results.

Pollan's path into psychedelic research

Pollan built his career writing about food before "How to Change Your Mind" opened a broader shift in public conversation. He traces his interest to reporting on Roland Griffiths' research at Johns Hopkins, which gave psilocybin to people with terminal cancer diagnoses; several, he says, described a lasting shift in how they related to death. Griffiths' 2006 paper on the mystical qualities of the experience, in Pollan's account, reopened the field after decades of dormancy. He notes LSD was studied at conferences and tested for alcoholism in the 1950s, before research was shut down for roughly three decades, a halt he partly attributes to the Nixon-era drug war.

Screening, guides, and "set and setting"

Pollan says people with a personal or family history of schizophrenia or bipolar disorder are typically excluded from psychedelic studies due to psychosis risk. For others, he stresses "set and setting," a person's internal state and physical environment, as central to outcome: a therapeutic session usually means lying down, wearing eyeshades, and listening to music with a trained guide present, unlike recreational use. Psylopedia's set and setting guide covers this further.

Pollan's own experience, and a "softened" ego

Pollan describes an LSD session in which he saw his wife, son, and parents in a "life review," emerging with a lasting sense that love matters most, and a separate account of perceiving two trees in his garden as his mother and father. He says such insights feel unusually persistent, more like "revealed knowledge" than an ordinary opinion, and links this to a temporary softening, once a full disappearance, of the ego, a self-protective inner voice people often mistake for their whole identity. Psylopedia's ego death article covers this further.

Bob Parsons: PTSD and "coming home" after 49 years

Parsons describes carrying PTSD after combat in Vietnam starting at age 17, including a quick temper he says cost him two marriages. After reading Pollan's book, he underwent a multi-day guided retreat in Hawaii combining ayahuasca and psilocybin. His wife noticed a change immediately afterward; he says the experience taught him, for the first time, how to feel loved, a shift he sums up as finally "coming home" 49 years after the war. He and his wife Renee have since funded a psychedelic research center at Mount Sinai; he frames wider legal access as his personal hope, not a settled outcome.

A father and daughter on trauma, OCD, and anxiety

Dave describes a guided psilocybin session in his 50s to work through unresolved childhood questions. His daughter Reagan, who has OCD and anxiety, describes a psilocybin experience in college as the first time her intrusive, racing thoughts fully quieted. Both credit an experienced guide with making the process safer than the recreational session Dave tried as a teenager.

What the early evidence suggests, and its limits

Pollan says current trials remain small, around a couple hundred participants, but some report lasting results, including a Yale trial in which people with OCD reported what he calls permanent relief. He relays a theory from a prominent psychiatrist that OCD, depression, anxiety, and addiction may be different expressions of one underlying pattern of rigid thought, illustrated with a metaphor of thoughts as sled tracks worn into snow that psychedelics can briefly smooth over, an emerging hypothesis, he stresses, not an established mechanism. On mainstream medicine, he notes the FDA regulates drugs, not therapy, yet what is studied is really psychedelic-assisted psychotherapy, where the guide is central; he cautions that unsupervised high-dose use carries real risk, including difficult experiences that can last a long time.

Microdosing: popular, largely unstudied

Asked about microdosing (sub-perceptual, roughly a tenth of a full dose, cycled with days off), Pollan says formal research is scarce, since review boards are reluctant to let people take a psychoactive drug and then drive. Many report improved mood, he says, but this could reflect a genuine drug effect, a placebo effect, or both: "the science is not in yet." Psylopedia's microdosing research overview covers what current studies do and do not show.

Grief, legal access, and defining "spiritual"

Natalie describes a guided psilocybin experience after prolonged grief following her father's death, saying it deepened her sense of connection to her family. Asked how to pursue this legally, Pollan points to two paths: a clinical trial (searchable at trials.gov), or Oregon or Colorado, where supervised psilocybin services are state-legal even though psilocybin remains a federal crime. Psylopedia's overview of psychedelic legal status covers this patchwork further.

Pollan says he does not consider himself religious but defines "spiritual" as deep connection to something beyond oneself, calling its opposite egotistical rather than materialistic. He and Oprah discuss meditation as a non-drug path to related states, slower to access but more sustainable, since psychedelics are not something people can or should use often. Psilocybin recurs across nearly every guest's story; Psylopedia's psilocybe cubensis profile covers its effects and research status.

Key takeaways

• ●Michael Pollan, journalist, Harvard professor, and author of "How to Change Your Mind," anchors the discussion; guests share personal accounts, not clinical data.
• ●People with a personal or family history of schizophrenia or bipolar disorder are typically excluded from psychedelic studies due to psychosis risk.
• ●"Set and setting," plus a trained guide, are described as central to a safe, therapeutic experience, distinct from recreational use.
• ●Bob Parsons, a Vietnam veteran, describes lasting relief from decades of PTSD symptoms after a guided retreat combining ayahuasca and psilocybin.
• ●Early trials, including one at Yale for OCD, report positive results, but Pollan stresses study sizes remain small and research is ongoing.
• ●Microdosing is popular but largely unstudied; reported benefits may reflect a placebo effect, a drug effect, or both.
• ●Legal access in the US runs through clinical trials or the state-regulated psilocybin services in Oregon and Colorado; psilocybin remains a federal crime.
• ●Pollan frames "spiritual" as deep connection rather than belief in the supernatural, and meditation as a sustainable, drug-free path to similar states.